Its benefits extend to cellular repair, anti-inflammatory effects, antioxidant protection, and improved tissue regeneration
That means you cannot legitimately place 10.8% for cagrilintide next to 24.2% for retatrutide and declare a winner, because those numbers come from different trials, different populations, different durations (26 vs 48 weeks), different doses, and critically a monotherapy figure for one versus a monotherapy figure for the other, while cagrilintides strongest data are actually as a combination
The other is appearance-related interest, especially skin clarity and overall radiance
They stress that there is little evidence of benefit for healthy people and that the treatments can be very expensive
Lopez-Maury, L., Sanchez-Riego, A
Recommended Target